Cargando…
FTY720 attenuates excitotoxicity and neuroinflammation
BACKGROUND: FTY720 (fingolimod, Gilenya™), a structural analog of sphingosine-1-phosphate (S1P), is the first oral drug approved for treatment the relapsing-remitting form of multiple sclerosis (MS), and its efficacy has been related to induced lymphopenia and consequent immunosuppression via modula...
Autores principales: | Cipriani, Raffaela, Chara, Juan Carlos, Rodríguez-Antigüedad, Alfredo, Matute, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429813/ https://www.ncbi.nlm.nih.gov/pubmed/25953296 http://dx.doi.org/10.1186/s12974-015-0308-6 |
Ejemplares similares
-
Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury
por: Cipriani, Raffaela, et al.
Publicado: (2017) -
FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017) -
Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation
por: Wu, Celina, et al.
Publicado: (2013) -
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017) -
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015)